Raymond J. Dingledine

Biography

Dr. Raymond J. Dingledine, PhD Founded Neurop, Inc(also known as NeurOp Corporation) in 2002. Dr. Dingledine is widely recognized as one of the foremost experts in the field of neuropharmacology. His research focuses primarily on the role of glutamate systems and associated receptors, and their role in disease indications involving seizures, such as epilepsy, with particular emphasis on the pH-dependent activity of potential neuroprotective NMDA receptor antagonists. In addition to publishing over 150 research papers during his career, he is the past Editor of Molecular Pharmacology, and presently serves on four Editorial Boards. He serves as a Member of Scientific Advisory Board of NeurOp Corporation. He serves on the scientific advisory boards of a privately-held biotech firm and a focused neuroscience investment fund. Dr. Dingledine is the recipient of numerous scientific honors and awards, including a Javits Neuroscience Investigator Award from the NIH, the Epilepsy Research Award from the American Epilepsy Society, two Bristol-Myers Squibb Neuroscience Awards, and the PhRMA Career Excellence Award. He serves as Director of Neurop, Inc. He served as a Treasurer of the Society for Neuroscience and serves on the Scientific Council of NINDS. He has served on a variety of NIH and National Science Foundation review panels, consulted for three major pharmaceutical companies. He is Professor and Chairman of the Department of Pharmacology at the Emory University School of Medicine in Atlanta, GA. Prior to coming to Emory in 1992, Dr. Dingledine was a Professor in the Department of Pharmacology at the University of North Carolina, Chapel Hill. He was profiled in Nature Medicine (vol 8 p 772, 2002). Dr. Dingledine received his Ph.D. in Pharmacology from Stanford University.

Research Interest

Spine Research